This education seminar is organised by the PRISMAP standards and harmonisation group and will give insight in the many components needed to better understand translating novel non-conventional radionuclides into radiopharmaceuticals for clinical application.
Please join us to learn more about PRISMAP, the European medical radionuclide programme with the coordinator Thierry Stora, a world renown physicist from CERN. The programme will further explore the many facets of novel radionuclide production by Mikael Jensen from Hervesy Labs at the Danish Technical University in Denmark and Ferid Haddad from Arronax in France. Clemens Decristoforo, a radiopharmacist from Medical University Innsbruck in Austria will highlight the critical role of the EU Pharmaceutical Regulations for novel radionuclides in radiopharmaceutical research and development. Eleni Gourni from the University Hospital Bern in Switzerland will close the event with a discussion on the development of theranostics in radiopharmacy. Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues.
13:00 | What is PRISMAP |
13:40 | Novel radionuclides and their production |
14:50 | EU Pharmaceutical Regulations |
16:00 | Development of Theranostic Radiopharmaceuticals |